Puretech Health Plc · LSE:PRTC
Puretech Health — Technical Presentation (March 2026)
14 slides from Puretech Health's technical presentation, March 2026
Slide 1: LYT-200 (Galectin-9 targeting mAb): Supplemental Slides
LYT-200 (Galectin-9 targeting mAb): Transforming treatment paradigms for hematologic malignancies Supplemental Slides
Slide 2: Table of Contents
Table of Contents Executive Summary AML: Aggressive Blood Cancer with Suboptimal Treatment Options Phase 1b Trial 2
Slide 3: Executive Summary
bad : BURETECH = o GIVING LIFE TO SCIENCE”
Slide 4: LYT-200: Potential First-in-class Therapy for AML/MDS
LYT-200: Potential First-in-class Therapy for AML/MDS Fully human IgG4 monoclonal antibody targeting galectin-9; First-in-class mutation agnostic Gear 1: Direct cell killing by inducing apoptosis/DNA damage Novel Two-Gear MOA Gear 2: Relief of immunosuppression through re-engaging T cells, NK cells
Slide 5: Galectin-9 is the Foundational Driver of Leukemia
Galectin-9 is the Foundational Driver of Leukemia A pro-leukemic protein, key immunosuppressor, and driver of AML/MDS microenvironment Overexpressed on AML/MDS stem cells but not on normal hematopoietic stem cells1,2,3,4,5 Higher expression in patients for whom frontline therapy and transplant fail2
Slide 6: Unique Two Gear MOA Results in Potent Biological Effect
Unique Two Gear MOA Results in Potent Biological Effect Challenge • Current therapies predominantly only address Gear 1 or Gear 2 LYT-200 Gear 1 Gear 2 Solution Kills cancer cells Kills cancer cells directly through activation of • Novel therapeutics that address both the immune system Gear 1 and Ge
Slide 7: Acute Myeloid Leukemia (AML): Aggressive Blood Cancer with Suboptimal Treatment Options
Acute Myeloid Leukemia (AML): Aggressive Blood Cancer with Suboptimal Treatment Options 7
Slide 8: AML is an Aggressive Blood Cancer with Suboptimal Treatment Options
AML is an Aggressive Blood Cancer with Complex Biology, Suboptimal Treatment Options, and No Cure Most AML patients become relapsed/refractory to treatment within 1 – 3 years after initial therapy In the first year In 1-3 years ~5.3 mo ~450,000 Median overall survival ~100% >80% in early R/R setting
Slide 9: The AML Journey: Rapid Decline Despite Treatment
The AML Journey: Rapid Decline Despite Treatment Critical efficacy and safety needs remain even with recent therapeutic advances Patient Journey: Diagnosis to Relapse 1L Tx Transplant R/R AML Stem Cell Median Chemotherapy Ven + HMA Overall Transplant Survival AML Low Dose Following Ven + HMA Diagnos
Slide 10: Phase 1b Trial
Phase 1b Trial bad : BURETECH = o GIVING LIFE TO SCIENCE”
Slide 11: Phase 1b Clinical Trial Design in R/R AML and High-Risk MDS
Phase 1b Clinical Trial Design in R/R AML and High-Risk MDS 39 patients enrolled in single agent cohort, 62 patients enrolled in combination cohort DOSE FINDING (4+2 DESIGN WITH BACKFILLS) Part 1 Part 2 (Single Agent) (Combination) Cohort 1: 2.0 mg/kg IV QW Cohort 1: 4.0 mg/kg IV QW Expansion at 12
Slide 12: Survival Efficacy
Data Cut from Phase 1b Trial in AML/MDS1 Presented at ASH LYT-200 Phase 1b Early Data2 Proposed Phase 2 Dose 12 mg/kg in Combination with Ven/Aza in Evaluable Patients3 (N=32) Median Progression-free 4.5 months Survival Survival Median Overall Survival 13.2 months 38% Combined Complete Response 43%
Slide 13: Durable Survival: Patients on LYT-200 and LYT-200 + VEN/HMA
Durable Survival: Patients on LYT-200 and LYT-200 + VEN/HMA live > 2-3x longer without overlapping toxicity LYT-200 Single LYT-200 + Ven/HMA LYT-200 + Ven/HMA SOC Agent (All doses) (All doses) (Proposed Phase 2 dose) Progression Free Survival (PFS) MONTHS 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Overall Sur
Slide 14: Favorable Safety and Tolerability Profile
Favorable Safety and Tolerability Profile No added toxicity; compatible with VEN/HMA and other R/R and frontline regimens Grade 1 & 2 nausea, diarrhea, rash, pruritus, fatigue, recording as possibly related No overlapping toxicity with VEN/HMA to LYT-200 in <25% of patients LYT-200 Suited for combin
PureTech Health — Technical Presentation (March 2026) on 6ix